ELDN supply chain intelligence for Eledon Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Eledon Pharmaceuticals, Inc. (ELDN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LONZA-SALES-AG-INC | LONZA-SALES-AG-INC | 90% | we have acquired rights to tegoprubart and other product candidates through a license agreement with The ALS Therapy Development Institute and a manufacturing know-how rights license agreement with L… |
| THE-ALS-THERAPY-DEVELOPMENT-FOUNDATION-INC | THE-ALS-THERAPY-DEVELOPMENT-FOUNDATION-INC | 90% | we have acquired rights to tegoprubart and other product candidates through a license agreement with The ALS Therapy Development Foundation, Inc. |
| THE-ALS-THERAPY-DEVELOPMENT-INSTITUTE | THE-ALS-THERAPY-DEVELOPMENT-INSTITUTE | 90% | In May 2015, Anelixis executed a License Agreement (the “Agreement”), which is an exclusive patent rights agreement with ALS Therapy Development Institute (“ALS TDI”) for certain patents and “know-ho… |
| NCEL | NewcelX Ltd. | 72% | Reciprocal relationship from NCEL graph: gulatory authority approvals to do so. The facilities and quality systems of some or all of its collaborators and third-party contractors must pass a pre-appr… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ELDN graph: ation fees for supplemental applications with clinical data. Drug manufacturers are subject to periodic unannounced … |
| ORANY | ORANY | 72% | ation fees for supplemental applications with clinical data. Drug manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Ch… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: asures are also imposed by health… |
| SNYNF | Sanofi | 72% | asures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United States regarding difficulty and cost for … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| COASTLANDS-CAPITAL-PARTNERS-LP | COASTLANDS-CAPITAL-PARTNERS-LP | 80% | Coastlands Capital agreed to exchange 4,203,764 shares of the Company’s common stock for a pre-funded warrant to purchase an aggregate of 4,203,764 shares of common stock |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ELDN graph: ation fees for supplemental applications with clinical data. Drug manufacturers are subject to periodic unannounced … |
| ORANY | ORANY | 72% | ation fees for supplemental applications with clinical data. Drug manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Ch… |
| SNYNF | Sanofi | 72% | asures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United States regarding difficulty and cost for … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: asures are also imposed by health… |
| ANELIXIS-THERAPEUTICS-INC | ANELIXIS-THERAPEUTICS-INC | 62% | be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to all… |
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | s stock price during the period. The warrant liability increased from $11.4 million as of December 31, 2025 to $30.4 million as of March 31, 2026. By comparison, for the three months ended March 31, … |
| CORPORATE-INFORMATION-OTIC-PHARMA-LTD | CORPORATE-INFORMATION-OTIC-PHARMA-LTD | 62% | be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to all… |
| LONZA-SALES-AG-INC | LONZA-SALES-AG-INC | 62% | ws, restrictions, and other regulatory measures imposed in international jurisdictions present similar challenges to those in the United States, including increased difficulty and cost in obtaining m… |
| NOVUS-THERAPEUTICS-INC | NOVUS-THERAPEUTICS-INC | 62% | be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to all… |
| TOKAI-PHARMACEUTICALS-INC | TOKAI-PHARMACEUTICALS-INC | 62% | be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to all… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ELDN-DEBT | Debt stack $555,000 | 90% | Market cache reports total debt of $555,000. |
| ELDN-DEBT-9264 | Warrants outstanding: 0.001 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| ELDN-DEBT-9265 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2016-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ELDN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 124 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| GRDX | GridAI Technologies Corp. | 100.00 | 2 |